AR028970A1 - USE OF CILANSETRON OR ITS SALTS BY ADDITION OF CIDOS AND / OR PHARMACOLOGICALLY COMPATIBLE SOLVATES FOR THE OBTAINING OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND / OR PROFILAXIS OF THE IRRITABLE INTESTINE SYNDROME - Google Patents

USE OF CILANSETRON OR ITS SALTS BY ADDITION OF CIDOS AND / OR PHARMACOLOGICALLY COMPATIBLE SOLVATES FOR THE OBTAINING OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND / OR PROFILAXIS OF THE IRRITABLE INTESTINE SYNDROME

Info

Publication number
AR028970A1
AR028970A1 ARP010102958A ARP010102958A AR028970A1 AR 028970 A1 AR028970 A1 AR 028970A1 AR P010102958 A ARP010102958 A AR P010102958A AR P010102958 A ARP010102958 A AR P010102958A AR 028970 A1 AR028970 A1 AR 028970A1
Authority
AR
Argentina
Prior art keywords
cilansetron
treatment
cidos
profilaxis
salts
Prior art date
Application number
ARP010102958A
Other languages
Spanish (es)
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10123447A external-priority patent/DE10123447A1/en
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of AR028970A1 publication Critical patent/AR028970A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de Cilansetron para el tratamiento de pacientes de IBS masculinos no estrenidos.Use of Cilansetron for the treatment of unstretched male IBS patients.

ARP010102958A 2000-07-26 2001-06-21 USE OF CILANSETRON OR ITS SALTS BY ADDITION OF CIDOS AND / OR PHARMACOLOGICALLY COMPATIBLE SOLVATES FOR THE OBTAINING OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND / OR PROFILAXIS OF THE IRRITABLE INTESTINE SYNDROME AR028970A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10036645 2000-07-26
DE10123447A DE10123447A1 (en) 2000-07-26 2001-05-14 Cilansetron-containing medicines for the treatment of non-obstipative male IBS patients

Publications (1)

Publication Number Publication Date
AR028970A1 true AR028970A1 (en) 2003-05-28

Family

ID=26006529

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102958A AR028970A1 (en) 2000-07-26 2001-06-21 USE OF CILANSETRON OR ITS SALTS BY ADDITION OF CIDOS AND / OR PHARMACOLOGICALLY COMPATIBLE SOLVATES FOR THE OBTAINING OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND / OR PROFILAXIS OF THE IRRITABLE INTESTINE SYNDROME

Country Status (16)

Country Link
EP (1) EP1307195A2 (en)
JP (1) JP2004504343A (en)
CN (1) CN1444479A (en)
AR (1) AR028970A1 (en)
AU (1) AU2001276409A1 (en)
BR (1) BR0112690A (en)
CA (1) CA2417677A1 (en)
CZ (1) CZ2003158A3 (en)
HU (1) HUP0301479A2 (en)
IL (1) IL153972A0 (en)
MX (1) MXPA02012917A (en)
NO (1) NO20030373L (en)
PL (1) PL363517A1 (en)
RU (1) RU2003104798A (en)
SK (1) SK1272003A3 (en)
WO (1) WO2002007713A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
RU2314808C2 (en) * 2004-01-30 2008-01-20 Астеллас Фарма Инк. Means for treating irritated intestine syndrome cases with diarrhea predominance
WO2005073220A1 (en) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Remedy for irritable bowel syndrome with diarrhea
JP4632204B2 (en) * 2005-09-21 2011-02-16 アステラス製薬株式会社 Antidiarrheal irritable bowel syndrome treatment
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
IL153972A0 (en) 2003-07-31
PL363517A1 (en) 2004-11-29
CN1444479A (en) 2003-09-24
WO2002007713A3 (en) 2002-11-14
CA2417677A1 (en) 2003-01-27
BR0112690A (en) 2003-06-24
CZ2003158A3 (en) 2003-08-13
JP2004504343A (en) 2004-02-12
RU2003104798A (en) 2004-06-27
NO20030373D0 (en) 2003-01-24
EP1307195A2 (en) 2003-05-07
NO20030373L (en) 2003-01-24
MXPA02012917A (en) 2003-05-14
SK1272003A3 (en) 2003-07-01
AU2001276409A1 (en) 2002-02-05
WO2002007713A2 (en) 2002-01-31
HUP0301479A2 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
AR037109A1 (en) USE OF FLIBANSERINE
ECSP088296A (en) THERAPEUTIC COMPOUNDS
HN2002000275A (en) DERIVATIVES OF 1.8 NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
CO5011096A1 (en) MEDICINES CONTAINING ANTAGONISTS OF THE 5-HT3 RECEPTOR FOR THE TREATMENT OF IBS
TR199901077A2 (en) �spen�iyari form�lasyonlar.
ECSP034774A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
HN2002000266A (en) PREPARATION AND USE OF IMIDAZOL DERIVATIVES FOR THE TREATMENT OF OBESITY.
IS7431A (en) Conjugates of drugs or cytotoxic agents and biologically active peptides
UY28348A1 (en) NEW COMPOUNDS
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
PA8803201A1 (en) ACID DERIVATIVES OF CICLOALQUILAMINO
UY27455A1 (en) DERIVATIVES N- (1,4,5,6-TETRAHIDRO-CICLOPENTAPIRAZOL -3-IL) - REPLACED. ITS OBTAINING AND USE AS DRUGS.
UY26370A1 (en) "IMIDAZO-5-IL-AMICAS BICÍCLICAS, DRUGS CONTAINING THEM, THEIR USE FOR THE PREPARATION OF DRUGS AND PROCEDURE FOR THE PREPARATION".
GT200000077A (en) MUTUAL SALT OF AMLODIPINO AND ATORVASTATINA
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
AR114270A1 (en) 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
AR025330A1 (en) COMBINATION OF ACTIVE SUBSTANCES WITH CLONIDINE
CO5700723A2 (en) USE OF A SPECIFIC CYCLIC AMINE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS TO TREAT AND PREVENT CARDIAC INSUFFICIENCY
ES2422081T3 (en) Peptide Ser-Ser-Ser-Arg and its medicinal uses
ATE302776T1 (en) CONDENSED PYRIDOINDOLE DERIVATIVES
AR028970A1 (en) USE OF CILANSETRON OR ITS SALTS BY ADDITION OF CIDOS AND / OR PHARMACOLOGICALLY COMPATIBLE SOLVATES FOR THE OBTAINING OF PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT AND / OR PROFILAXIS OF THE IRRITABLE INTESTINE SYNDROME
ES2193065T3 (en) NEW USE OF THE SAREDUTANT.
DK1353948T3 (en) Soluble biological analogs for beta-amyloid peptide
ECSP003551A (en) PHARMACEUTICAL COMPLEX
HUP0204208A2 (en) Antipruritic agents for external use

Legal Events

Date Code Title Description
FB Suspension of granting procedure